TiumBio plans to initiate a Phase 1b clinical trial of #TU7710, a long-acting recombinant activated factor VII, in patients with #hemophilia in Europe. Read more at https://lnkd.in/ggi24Trc
TiumBio’s Post
More Relevant Posts
-
Should we say #Prediction? Yes, Daniel, you can plug in your #Tregitope-Adjusted #EpiMatrix score and get an estimation of potential immunogenicity in the clinic (ADA)! Here's the publication Raj! https://lnkd.in/e569CDPC Here's the detailed caption: Twenty-two licensed antibodies make up the polynomial regression used for predicting T-dependent ADA responses in ISPRI (orange line). The updated regression model adds 21 new mAb examples with clinical immunogenicity data (total of 43). Observed immunogenicity indicates the percent of exposed patients with a positive immunogenic response as defined by a positive ADA titer and reported from clinical trials identified in the FDA-approved drug product labels.
To view or add a comment, sign in
-
Establishing a patient’s pharmacogenomic profile enables optimized, individualized medication selection with personalized insights on drug response and adverse reactions. Learn more about our pharmacogenomics testing. https://bit.ly/3Rf1B5n
Pharmacogenomics - Insights
news.mayocliniclabs.com
To view or add a comment, sign in
-
Did you know pharmacogenomics testing can help prevent adverse drug reactions? Our testing focuses on clinically actionable genes and provides superior analytical and clinical quality, enabling the detection of more alleles than other testing. Learn more. https://bit.ly/4d3Vs4G
Pharmacogenomics - Insights
news.mayocliniclabs.com
To view or add a comment, sign in
-
🦠 It is standard practice to test new drug molecules in vivo in two preclinical species to: - gain a more detailed understanding of how they are transported and eliminated through the kidney - mitigate risk of renal toxicity in humans What if you could predict more reliably the response in human and understand cross-species variability ahead of clinical trials? 🤔 The aProximate™ proximal tubule cells model offers a powerful tool to compare transporter activity and drug efficacy and safety across different species to improve in vitro-in vivo extrapolation (IVIVE). Find out more about cross-species comparison of drug handling with near-physiological kidney transporter model: https://lnkd.in/eWaFtAQr #Newcells #InVivo #RenalToxicity #ClinicalTrials
To view or add a comment, sign in
-
I've added a new blog post to my website with some thoughts on the recent review from P. Ryan Potts, Ph.D. and the Amgen team on how the induced-proximity landscape is shaping up. I speculate why PROTACs may be a great use case and how some areas could be easier than others to develop. Please go take a look and add any comments. #tpd #amgen #inducedproximity #drugdiscovery https://lnkd.in/eWGpSsJb
19th January 2024
janusdrugdiscovery.com
To view or add a comment, sign in
-
C-Path's Collin Hovinga and Sakshi S. are speaking at this week's 3rd Annual ALS Drug Development Summit. Session and panel information: Sakshi Sardar Clinical Track | May 22 | 2 pm | Supporting Drug Development in ALS Through the Use of Digital Health Technologies Collin Hovinga Clinical Track | May 23 | 10:45 am | Panel Discussion: Striving for Consensus on the Level of Evidence Required for Approval May 23 | 3:40 pm | Panel Discussion: Exploring Ongoing Research Efforts Globally in ALS: How Will Future Study Read-Outs Transform the ALS Landscape? Learn more at: https://lnkd.in/g5gVJaKc C-Path's Critical Path for Rare Neurodegenerative Diseases (CP-RND) brings together experts in rare neurodegenerative diseases like ALS, biopharmaceutical companies, regulators, patient communities, and advocacy organizations to enhance our understanding of disease pathology, treatment options, diagnostics, and drug development. Learn more: https://lnkd.in/gf-2fr-f #CPath #ALS #drugdevelopment #ALSAwarenessMonth #raredisease #datasharing #collaboration #digitalhealth
To view or add a comment, sign in
-
There is a rising need for #smallmolecule drug discovery with the onset of more chronic diseases worldwide. According to Yahoo Finance, the market is projected to reach USD 83.6 Billion by 2030: "With a growing emphasis on precision medicine and personalized therapies, the Small Molecule Drug Discovery Market is positioned for continued growth and innovation, contributing to the development of novel therapeutic interventions across a spectrum of medical conditions." Curadev is proud to be a part of this movement forward. https://lnkd.in/ehpDRZs7
Small Molecule Drug Discovery Market projected to reach USD 83.6 Billion by 2030, growing at a CAGR of 8.98% during the forecast period of 2023-2030 - pronounced by MarketDigits in its recent study
finance.yahoo.com
To view or add a comment, sign in
-
Things are happening at InCarda!!! Read all about it: https://lnkd.in/gFUX8e2D Analysis of the results of the RESTORE-1 Phase 3 trial following its premature termination demonstrated statistically significant cardioversion of PAF with orally inhaled flecainide, providing compelling rationale for the continued development of FlecIH-103 in the target population of PAF patients. — The RESTORE-1 trial was stopped prematurely due to lower-than-expected efficacy and plasma flecainide levels during a blinded review of the data — There were no safety concerns associated with the administration of FlecIH-103 A novel drug delivery platform has shown the potential to enable efficient and reliable delivery of flecainide to the heart through the lung, appropriate for both hospital and home use Bridging Phase 1 study data to date establishes a path for future registration trials
InCarda Therapeutics Announces Results From the RESTORE-1 Phase 3 Trial and Plans for Continued Development
optout.businesswire.com
To view or add a comment, sign in
-
Thoughts on this? >> Over a year after FDA rejection, Biohaven claims success in pivotal muscle disease study >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #healthcare #biotech #pharmaceutical #pharma #productmarketing
Over a year after FDA rejection, Biohaven claims success in pivotal muscle disease study
endpts.com
To view or add a comment, sign in
-
It was a pleasure to be part of this year’s RAS-Targeted Drug Development Summit, joining peers across the sector to discuss the exciting potential of targeted protein degradation (#TPD) to tackle RAS pathway– here’s what I took from it: 1. Since TPD was first applied to drug discovery, we have made significant progress. There are multiple potential advantages of protein degraders over inhibitor-based approaches to be confirmed at clinical stage, as well as potential issues we need to solve as a modality. 2. There is no ‘one-size-fits-all’ in modality selection. Selecting the best approach for the disease and underlying biology being targeted is key. Both monovalent and bivalent molecules have pros and cons. 3. More must be done if we are to maximize the potential of TPD for patients. Deepening our understanding of potential resistance mechanisms will help us refine our patient populations and combination strategies. At Astellas, we are deeply committed to advancing TPD, a modality we believe could redefine what’s possible in treating some of the world’s most devastating diseases – if you are interested in partnering with us, please reach out! #ScienceFirstForPatients #ChangingTomorrow https://lnkd.in/gaFBnmgV
To view or add a comment, sign in
307 followers